CLINICAL ROLE -
Opdualag From Bristol Myers Squibb
Combination therapy with both nivolumab and relatlimab leads to increased T-cell activation compared with monotherapy with either agent alone.
New FDA Actions: Merck & Co Inc's Isentress
The FDA approved an expanded indication for Isentress (raltegravir) to include the treatment of HIV-1 infection in children 2 years and older.
2 Clarke Drive Cranbury, NJ 08512